board of directors

Ted Fjällman

Ted Fjällman is CEO at Flerie Invest and member of the Boards of several of Flerie’s portfolio companies including, Alder Therapeutics, Amarna Therapeutics, Geneos Therapeutics, NorthX Biologics, Prokarium, XNK Therapeutics, and is a Director of Tekiu Ltd. His previous assignments include positions as CEO of Prokarium and in clinical research at Sahlgrenska University Hospital as well as in strategy consulting at Sweden’s Royal Academy of Engineering Sciences. Ted holds a Ph.D. in Biotechnology and Immunology from the University of Guelph, Canada.


Anders Ekblom

Anders Ekblom spent two decades at AstraZeneca, as a member of global executive teams including roles as Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and CEO of AstraZeneca AB Sweden. He has previously been Chairman of the Board of the Karolinska University Hospital and board member of the Swedish Research Council.
Dr. Ekblom recently joined Flerie’s Board of Directors, and currently also serves as Chairman of the Board of Directors and Board Member for several biopharmaceutical start-ups. Anders Ekblom is a board-certified MD in Anesthesiology and Intensive Care, PhD, Doctor of Dental Surgery, and serves as an Associate Professor at the Karolinska Institute in Sweden.


Michel Briejer

Michel Briejer is a Managing Partner at Thuja Capital, which he joined early 2008. Prior to that, he held senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Michel holds an MSc degree in Pharmacy from Utrecht University and a PhD in Pharmacology from Wageningen University, as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med.) from the European Center for Pharmaceutical Sciences in Basel.


Erik Manting

Erik Manting is CEO of Mendus AB, a publicly listed cancer immunotherapy company. After obtaining an MSc in Medical Biology and a PhD in Molecular Microbiology, Erik worked for several years in the field of immunology before switching to investment banking. Overall, he spent 15 years in different commercial and management roles and five years as Executive Director Corporate Finance at Kempen & Co, a leading European investment bank with a focus on Life Sciences & Healthcare. Erik has been involved with Synerkine Pharma since 2017 and represents the founders in the board.